CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...

Japanese drugmaker Eisai revealed that its in-house discovered tyrosine kinase inhibitor, Lenvima (lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial ...

Immutep is continuing the AIPAC-003 trial, which enrolled 71 metastatic hormone receptor positive (HR+), HER2-negative/low or ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

While the fear of cancer looms large in the minds of many, the condition's vague indicators make it hard to know when genuine ...

Reduce development timelines and costs, while improving access to life-saving treatments VANCOUVER, BC / ACCESS Newswire / July 30, 2025 / Onco-Innovations Limited (CBOE ...

Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build momentum and is recruiting patients at a growing number of activated clinical ...

A global study reveals that cutting-edge cancer immunotherapies, while lifesaving, carry a hidden risk: they may trigger cholestasis, a serious liver condition where bile flow stalls.

Reduce development timelines and costs, while improving access to life-saving treatments VANCOUVER, BC / ACCESS Newswire / July 30, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfur ...

AI-powered quantification of tumor-infiltrating lymphocytes could change how patients with melanoma are treated after surgery ...

A global study reveals that cutting-edge cancer immunotherapies, while lifesaving, carry a hidden risk: they may trigger cholestasis, a serious liver ...